Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BCL2L12: a promising molecular prognostic biomarker in breast cancer.
Tzovaras A, Kladi-Skandali A, Michaelidou K, Zografos GC, Missitzis I, Ardavanis A, Scorilas A. Tzovaras A, et al. Among authors: missitzis i. Clin Biochem. 2014 Dec;47(18):257-62. doi: 10.1016/j.clinbiochem.2014.09.008. Epub 2014 Sep 16. Clin Biochem. 2014. PMID: 25230343
Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Ardavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, Chrysochoou M, Sotiropoulou A, Arnogiannaki N, Ioannidis G, Pissakas G, Rigatos G. Ardavanis A, et al. Among authors: missitzis i. Oncologist. 2006 Jun;11(6):563-73. doi: 10.1634/theoncologist.11-6-563. Oncologist. 2006. PMID: 16794236 Free article. Clinical Trial.
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Kountourakis P, Missitzis I, Doufexis D, Zobolas V, Pissakas G, Arnogiannaki N, Maliou S, Sotiropoulou A, Ardavanis A. Kountourakis P, et al. Among authors: missitzis i. J Cancer Res Clin Oncol. 2011 Feb;137(2):221-8. doi: 10.1007/s00432-010-0878-8. Epub 2010 Apr 13. J Cancer Res Clin Oncol. 2011. PMID: 20387073 Clinical Trial.
Increased frequency of CD4+ cells expressing CD161 in cancer patients.
Iliopoulou EG, Karamouzis MV, Missitzis I, Ardavanis A, Sotiriadou NN, Baxevanis CN, Rigatos G, Papamichail M, Perez SA. Iliopoulou EG, et al. Among authors: missitzis i. Clin Cancer Res. 2006 Dec 1;12(23):6901-9. doi: 10.1158/1078-0432.CCR-06-0977. Clin Cancer Res. 2006. PMID: 17145807
25 results